Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease

JAMA Neurology

Volumn 72, Issue 10, 2015, Pages 1175-1182

  Bäckström, David C ^a   Domellöf, Magdalena Eriksson ^a   Linder, Jan ^a   Olsson, Bob ^b   Öhrfelt, Annika ^b   Trupp, Miles ^a   Zetterberg, Henrik ^b,c   Blennow, Kaj ^b   Forsgren, Lars ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; FATTY ACID BINDING PROTEIN; HEART FATTY ACID BINDING PROTEIN; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC PARKINSONISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PARKINSONISM; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; ADULT; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COMPLICATION; EARLY DIAGNOSIS; MIDDLE AGED; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COHORT STUDIES; DEMENTIA; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK; TAU PROTEINS;

EID: 84944042857     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1449     Document Type: Article

References (39)

1. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406-412.
2. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2(4):229-237.
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-392.
4. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697-707.
5. Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445-1452.
6. Kang JH, Irwin DJ, Chen-Plotkin AS, et al; Parkinson's Progression Markers Initiative. Association of cerebrospinal fluid ß-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70(10):1277-1287.
7. Alves G, Brønnick K, Aarsland D, et al. CSF amyloid-ß and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2010;81(10):1080-1086.
8. Montine TJ, Shi M, Quinn JF, et al. CSF Aß42 and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010;25(15):2682-2685.
9. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid ß-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282-1289.
10. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology. 2000;54(10):1960-1964.
11. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64(10):850-855.
12. Steinacker P, Mollenhauer B, Bibl M, et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004;370(1):36-39.
13. McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol. 2013;13:35.
14. Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010;25(3):341-348.
15. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol. 1989;15(1):27-44.
16. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94-98.
17. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9.
18. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26(3):231-245.
19. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid ß-amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673-680.
20. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285(1):49-52.
21. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349-356.
22. Yarnall AJ, Breen DP, Duncan GW, et al; ICICLE-PD Study Group. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014;82(4):308-316.
23. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707.
24. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35.
25. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord. 1998;13(1):70-77.
26. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol. 2005;58(5):773-776.
27. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, De Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64(8):1404-1410.
28. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67(11):1931-1934.
29. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord. 2009;23(3):295-297.
30. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745-1748.
31. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008;115(4):409-415.
32. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid ß 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055-1061.
33. Alves G, Lange J, Blennow K, et al. CSF Aß42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784-1790.
34. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15(3):169-176.
35. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid ß-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78(5):461-464.
36. Halliday GM. Motor deficits associated with changes in ß-amyloid in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013;84(5):475-476.
37. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116-126.
38. Fournier N, Geoffroy M, Deshusses J. Purification and characterization of a long chain, fatty-acid-binding protein supplying the mitochondrial beta-oxidative system in the heart. Biochim Biophys Acta. 1978;533(2):457-464.
39. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol. 2013;106-107:17-32.